Assessment of endothelial damage and dysfunction: Observations in relation to heart failure

QJM: An International Journal of Medicine

Volumn 96, Issue 4, 2003, Pages 253-267

  Chong, A Y ^a   Blann, A D ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; RAMIPRIL; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VESSEL PERMEABILITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM LESION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVIEW; THROMBOGENESIS; VASODILATATION;

EID: 0037385373     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg037     Document Type: Review

References (148)

1. Virchow R. Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Frankfurt, Medinger Sohn and Co., 1856:219-732.
2. Lip GYH, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34:255-65.
3. Henderson AH. Endothelium in control. Br Heart J 1991; 65:116-25.
4. Pearson JD. Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol 1999; 12:329-41.
5. Pearson JD. Normal endothelial cell function. Lupus 2000; 9:183-8.
6. Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GAP, Latt SA, Orkin SH. Human von Willebrand Factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localisation. Science 1985; 228:1401-6.
7. Blann A. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 1993; 50:125-34.
8. Blann A, Seigneur M. Soluble markers of endothelial cell function. Clin Hemorheol Microcirc 1997; 17:3-11.
9. Ginsburg D, Konkle BA, Gill JC, Montgomery RR, Bockenstedt JL, Johnson TA, Yang AY. Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA. Proc Natl Acad Sci USA 1989; 86:3723-7.
10. Green D, Kucuk O, Haring O, Dyer A. The factor VIII complex in atherosclerosis: effects of aspirin. J Chronic Dis 1981; 34:21-6.
11. Ware RE, Parker RI, McKeown LP, Graham ML. A human chimera of von Willebrand disease following bone marrow tansplantation. Am J Paed Haematol Oncol 1993; 15:338-42.
12. Blann AD, Taberner DA. A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995; 90:244-8.
13. Hirokawa K, Aoki N. Up-regulation of thrombomodulin in human umbilical vein endothelial cells in vitro. J Biochem 1990; 108:839-45.
14. Pottinger BE, Read RC, Paleolog EG, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53:387-94.
15. Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 1997; 59:115-20.
16. Bloom AL. von Willebrand factor: clinical features of inherited and acquired disorders. Mayo Clin Proc 1991; 66:743-51.
17. Chan SY, Chan PH, Ho PC, Yam A. Factor VIII-related antigen levels in normal pregnancy and puerperium. Eur J Obstet Gynecol Reprod Biol 1985; 19:199-204.
18. Dahlman T, Hellgren M, Blomback M. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecol Obstet Invest 1985; 20:37-44.
19. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52:176-82.
20. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88:601-7.
21. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89:901-8.
22. Haines AP, Howarth D, North WR, Goldenberg E, Stirling Y, Meade TW, et al. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 1983; 50:800-3.
23. Jansson J, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66:351-5.
24. Blann AD, McCollum CN. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 1999; 10:375-80.
25. Wallberg-Jonsson S, Dahlen GH, Nilsson TK, Ranby M, Rantapaa-Dahlqvist S. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin.Rheumatol 1993; 12:318-24.
26. Nusinow SR, Federici AB, Zimmerman TS, Curd JG. Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum 1984; 27:1405-10.
27. Ames PR, Lupoli S, Alves J, Atsumi T, Edwards C, Iannaccone L, et al. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome. Br J Rheumatol 1997; 36:1045-50.
28. Blann AD, Sheeran TP, Emery P. von Willebrand factor: increased levels are related to poor prognosis in systemic sclerosis and not to tissue autoantibodies. Br J Biomed Sci 1997; 54:5-9.
29. Mannucci PM, Lombardi R, Lattuada A, Perticucci E, Valsecchi R, Remuzzi G. Supranormal von Willebrand factor multimers in scleroderma. Blood 1989; 73:1586-91.
30. Lee P, Norman CS, Sukenik S, Alderdice CA. The clinical significance of coagulation abnormalities in systemic sclerosis (scleroderma). J Rheumatol 1985; 12:514-17.
31. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 1998; 98:294-9.
32. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, Perlemuter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36:110-14.
33. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103:1746-51.
34. Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol 1995; 76:453-8.
35. Seigneur M, Dufourco P, Conri C, Constans J, Mercie P, Pruvost A, Boisseau M. Plasma thrombomodulin: new approach of endothelium damage. Int Angiol 1993; 12:355-9.
36. Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990; 75:329-36.
37. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264:4743-6.
38. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76:2024-9.
39. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73:159-65.
40. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-α: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991; 77:542-50.
41. Boehme MWJ, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP. Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: in vivo and in vitro studies. Immunology 1996; 87:134-40.
42. Gabat S, Keller C, Kempe HP, Amiral J, Ziegler R, Ritz E, et al. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus. Vasa 1996; 25:233-41.
43. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thromb Res 1993; 71:423-31.
44. Sernau T, Wilhelm C, Seyfert U, Gabath S, Henkels M, Amiral J, et al. Thrombomodulin is a marker of microvascular, but not for macrovascular endothelial cell damage. Vasa 1995; 24:347-53.
45. Borcea V, Morcos M, Isermann B, Henkels M, Ziegler S, Zumbach M, et al. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus. Vasa 1999; 28:172-80.
46. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353:1729-34.
47. Nilsson TK, Hellsten G, Amiral J. Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis 1993; 4:455-8.
48. Naruse M, Kawana M, Hifumi S, Naruse K, Yoshihara I, Oka T, et al. Plasma immunoreactive endothelin, but not thrombomodulin, is increased in patients with essential hypertension and ischemic heart disease. J Cardiovasc Pharmacol 1991; 17(Suppl. 7):S471-4.
49. Blann AD, Amiral J, McCollum CN. Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease. Br J Haematol 1996; 95:263-5.
50. Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 1997; 59:115-20.
51. Smith AP, Demoncheaux EA, Higenbottam TW. Nitric oxide gas decreases endothelin-1 mRNA in cultured pulmonary artery endothelial cells. Nitric Oxide 2002; 6:153-9.
52. Akazawa H, Ikeda U, Kuroda T, Shimada K. Plasma endothelin-1 levels in Takayasu's arteritis. Cardiology 1996; 87:303-5.
53. Hoffman GS, Ahmed AE. Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 1998; 66 (Suppl. 1):S191-4.
54. Boehme MW, Schmitt WH, Youinou P, Stremmel WR, Gross WL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996; 101:387-94.
55. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J 1991; 66:356-8.
56. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3:381-7.
57. Damas J, Gullestad L, Aukrust P. Cytokines as new treatment targets in chronic heart failure. Curr Control Trials Cardiovasc Med 2001; 2:271-7.
58. Blann AD, Lip GYH. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis 1998; 9:297-306.
59. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14:506-12.
60. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants and cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187:584-9.
61. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993; 171:223-9.
62. Sudhoff T, Germing U, Aul C. Levels of circulating endothelial adhesion molecules in patients with myelodysplastic syndromes. Int J Oncol 2002; 20:167-72.
63. Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001; 37:2392-7.
64. Kyriakou DS, Alexandrakis MG, Kyriakou ES, Liapi D, Kourelis TV, Passam F, et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol 2001; 80:577-83.
65. Blann AD, Amiral J, McCollum CN. Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease. Br J Haematol 1996; 95:263-5.
66. Blann AD, Waite MA. von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron Artery Dis 1996; 7:143-7.
67. Blann AD, Miller JP, McCollum CN. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997; 132:151-6.
68. Blann AD, Davis A, Miller JP, McCollum CN. Von Willebrand factor and soluble E-selectin in hyperlipidaemia: relationship to lipids and vascular disease. Am J Hematol 1997; 55:15-23.
69. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 1994; 72:151-4.
70. Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 1994; 12:925-8.
71. Andreassen AK, Nordoy I, Simonsen S, Ueland T, Muller F, Froland SS, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998; 81:604-8.
72. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336-42.
73. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 299:373-6.
74. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2(8670):997-1000.
75. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986; 8:37-44.
76. Griffith TM. Studies of endothelium-derived relaxant factor (EDRF), its nature and mode of action. Eur Heart J 1985; 6:37-49.
77. Macdonald P, Schyvens C, Winlaw D. The role of nitric oxide in heart failure. Potential for pharmacological intervention. Drugs Aging 1996; 8:452-8.
78. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 1999; 100:1983-91.
79. Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, Zelis R. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69:1596-601.
80. Arnold JM, Marchiori GE, Imrie JR, Burton GL, Pflugfelder PW, Kostuk WJ. Large artery function in patients with chronic heart failure. Studies of brachial artery diameter and hemodynamics. Circulation 1991; 84:2418-25.
81. Winlaw DS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM, Macdonald PS. Increased nitric oxide production in heart failure. Lancet 1994; 344:373-4.
82. Ikeda U, Shimada K. Nitric oxide and cardiac failure. Clin Cardiol 1997; 20:837-41.
83. Kelm M, Schafer S, Dahmann R, Dolu B, Perings S, Decking UK, et al. Nitric oxide induced contractile dysfunction is related to a reduction in myocardial energy generation. Cardiovasc Res 1997; 36:185-94.
84. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenfuss G. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998; 32:955-63.
85. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-15.
86. Colucci WS. Myocardial endothelin: does it play a role in myocardial failure? Circulation 1996; 93:1069-72.
87. Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC. The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 2001; 38(Suppl. 2):S49-52.
88. Ry SD, Andreassi MG, Clerico A, Biagini A, Giannessi D. Endothelin-1, endothelin-1 receptors and cardiac natriuretic peptides in failing human heart. Life Sci 2001; 68:2715-30.
89. Properzi G, Terenghi G, Gu XH, Poccia G, Pasqua R, Francavilla S, et al. Early increase precedes a depletion of endothelin-1 but not of von Willebrand factor in cutaneous microvessels of diabetic patients. A quantitative immunohistochemical study. J Pathol 1995; 175:243-52.
90. Best PJ, Lerman A. Endothelin in cardiovascular disease: from atherosclerosis to heart failure. J Cardiovasc Pharmacol 2000; 35(Suppl. 2):S61-3.
91. Ergul A. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Pharmacotherapy 2002; 22:54-65.
92. Fukuchi M, Giaid A. Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. J Cardiovasc Pharmacol 1998; 31(Suppl. 1):S421-3.
93. Vidal B, Roig E, Perez-Villa F, Orus J, Perez J, Jimenez V, et al. Prognostic value of cytokines and neurohormones in severe heart failure. Rev Esp Cardiol 2002; 55:481-6.
94. Selvais PL, Robert A, Ahn S, van Linden F, Ketelslegers JM, Pouleur H, et al. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J Card Fail 2000; 6:201-7.
95. Frey B, Pacher R, Locker G, Bojic A, Hartter E, Woloszczuk W, et al. Prognostic value of hemodynamic vs big endothelin measurements during long-term IV therapy in advanced heart failure patients. Chest 2000; 117:1713-19.
96. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997; 18:254-8.
97. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27:633-41.
98. Hurlimann D, Enseleit F, Noll G, Luscher TF, Ruschitzka F. Endothelin antagonists and heart failure. Curr Hypertens Rep 2002; 4:85-92.
99. Masaki T, Vane JR, Vanhoutte PM. International Union of Pharmacology nomenclature for endothelin receptors. Pharmacol Rev 1994; 46:137-42.
100. Spieker LE, Noll G, Ruschitzka FT, Luscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 2001; 37:1493-505.
101. d'Uscio LV, Barton M, Shaw S, Luscher TF. Endothelin in atherosclerosis: importance of risk factors and therapeutic implications. J Cardiovasc Pharmacol 2000; 35(Suppl. 2):S55-9.
102. Newby DE, Webb DJ. Advances in clinical pharmacology and therapeutics: endothelin. Br J Hosp Med 1996; 56:360-4.
103. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 16:1081-98.
104. Yoshizumi M, Kurihara H, Morita T, Yamashita T, Oh-hashi Y, Sugiyama T, et al. Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. Biochem Biophys Res Commun 1990; 166:324-9.
105. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46:325-415.
106. Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, et al. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 1989; 161:859-64.
107. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991; 88:1054-7.
108. See B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89:1203-8.
109. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752-6.
110. Morise T, Takeuchi Y, Kawano M, Koni I, Takeda R. Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995; 18:87-9.
111. Seligman BG, Biolo A, Polanczyk CA, Gross JL, Clausell N. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2000; 23:1395-400.
112. Baumgartner-Parzer SM, Wagner L, Reining G, Sexl V, Nowotny P, Muller M, et al. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997; 154:231-9.
113. Galatius S, Wroblewski H, Sorensen VB, Bie P, Parving HH, Kastrup J. Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation? Am Heart J 1999; 137:549-54.
114. Huang LQ, Whitworth JA, Chesterman CN. Effects of cyclosporin A and dexamethasone on haemostatic and vasoactive functions of vascular endothelial cells. Blood Coagul Fibrinolysis 1995; 6:438-45.
115. Geny B, Piquard F, Follenius M, Thiranos JC, Charpentier A, Epailly E, et al. Endothelin participates in increased circulating atrial natriuretic peptide early after human heart transplantation. J Heart Lung Transplant 1998; 17:167-75.
116. Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, Shimada K. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1997; 29:65-9.
117. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibilty. Br Heart J 1995; 74:247-53.
118. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:1111-15.
119. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human-peripheral conduit arteries in vivo. Circulation 1995; 91:1314-19.
120. Agewall S, Doughty RN, Bagg W, Whalley GA, Braatvedt G, Sharpe N. Comparison of ultrasound assessment of flow-mediated dilatation in the radial and brachial artery with upper and forearm cuff positions. Clin Physiol 2001; 21:9-14.
121. Doshi SN, Naka KK, Payne N, Jones CJ, Ashton M, Lewis MJ, et al. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin Sci (Lond) 2001; 101:629-35.
122. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24:1468-74.
123. Schroeder S, Enderle MD, Baumbach A, Ossen R, Herdeg C, Kuettner A, et al. Influence of vessel size, age and body mass index on the flow-mediated dilatation (FMD%) of the brachial artery. Int J Cardiol 2000; 76:219-25.
124. Deng YB, Wang XF, Le GR, Zhang QP, Li CL, Zhang YG. Evaluation of endothelial function in hypertensive elderly patients by high-resolution ultrasonography. Clin Cardiol 1999; 22:705-10.
125. Silber HA, Bluemke DA, Ouyang P, Du YP, Post WS, Lima JA. The relationship between vascular wall shear stress and flow-mediated dilation: endothelial function assessed by phase-contrast magnetic resonance angiography. J Am Coll Cardiol 2001; 38:1859-65.
126. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-65.
127. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104:191-6.
128. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Colch.) 1996; 91:567-73.
129. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84:1589-96.
130. Varin R, Mulder P, Tamion F, Richard V, Henry JP, Lallemand F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 2000; 102:351-6.
131. Katz SD, Biasucci L, Sabba C, Strom JA, Jondeau G, Galvao M, et al. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992; 19:918-25.
132. Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993; 88:55-61.
133. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994; 90:12-16.
134. Fichtlscherer S, Rossig L, Breuer S, Vasa M, Dimmeler S, Zeiher AM. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001; 104:3023-5.
135. Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J 1998; 19(Suppl. J):J7-15.
136. Joannides R, Bizet-Nafeh C, Costentin A, Iacob M, Derumeaux G, Cribier A, et al. Chronic ACE inhibition enhances the endothelial control of arterial mechanics and flow-dependent vasodilatation in heart failure. Hypertension 2001; 38:1446-50.
137. Giannattasio C, Achilli F, Grappiolo A, Failla M, Meles E, Gentile G, et al. Radial artery flow-mediated dilatation in heart failure patients: effects of pharmacological and nonpharmacological treatment. Hypertension 2001; 38:1451-5.
138. Kubo SH, Rector TS, Bank AJ, Tschumperlin LK, Raij L, Brunsvold N, et al. Effects of cardiac transplantation on endothelium-dependent dilation of the peripheral vasculature in congestive heart failure. Am J Cardiol 1993; 71:88-93.
139. Patel AR, Kuvin JT, Pandian NG, Smith JJ, Udelson JE, Mendelsohn ME, et al. Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation. J Am Coll Cardiol 2001; 37:195-200.
140. Hornig B, Arakawa N, Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 1998; 19(Suppl. G):G48-53.
141. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95:1115-18.
142. Hornig B, Drexler H. Endothelial function and bradykinin in humans. Drugs 1997; 54(Suppl. 5):42-7.
143. Monobe H, Yamanari H, Nakamura K, Ohe T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol 2001; 24:705-9.
144. Stys T, Lawson W, Smaldone G, Stys A. Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure? Arch Intern Med 2000; 160:1409-13.
145. Sun D, Huang A, Smith CJ, Stackpole CJ, Connetta JA, Shesely EG, et al. Enhanced release of prostaglandins contributes to flow-induced arteriolar dilation in eNOS knockout mice. Circ Res 1999; 85:288-93.
146. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999; 93:2951-8.
147. Solovey A, Lin Y, Browne PV, Wayner E, Choong S, Hebbel RP. Phenotypic analysis of circulating endothelial cells reveals an activated endothelium in sickle cell anemia. Blood 1996; 88(Suppl. 1):648a abstract.
148. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997; 337:1584-90.